[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"tako-tsubo-cardiomyopathy\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:tako-tsubo-cardiomyopathy":163},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,5,0,[8,59,90,115,143],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":22,"conditions":23,"keywords":37,"overallStatus":46,"whyStopped":4,"lastUpdateSubmitDate":47,"lastUpdatePostDateStruct":48,"startDateStruct":51,"completionDateStruct":53,"leadSponsor":55,"locationsCount":58},"100598885","eacvi-study-on-multimodality-cardiovascular-imaging-of-inflammatory-cardiovascular-diseases-100598885",false,"NCT07077304","EACVI Study on Multimodality Cardiovascular Imaging of Inflammatory Cardiovascular Diseases","EACVI-INFLAME","Inclusion Criteria:\n\n1. Age ≥ 18 years\n2. Ability to provide informed non-opposition\n3. Referred for a CMR and\u002For nuclear imaging exam\n\nAND a suspicion of one of the following ICARDs :\n\n1. Suspected Myocarditis (acute or chronic, and whatever the aetiologies)\n2. Suspected Myocardial Infarction with Non-Obstructive Coronary Arteries (MINOCA)\n3. Suspected Tako-Tsubo\n4. Suspected Pericarditis (acute or chronic, and whatever the aetiologies)\n5. Suspected Connective tissue disease with cardiovascular involvement:\n\n   * Systemic sclerosis\n   * Systemic lupus erythematosus\n   * Antiphospholipid syndrome\n   * Idiopathic inflammatory myopathies\n   * Rheumatoid arthritis, spondylarthritis\n6. Suspected Vasculitis with cardiovascular involvement:\n\n   * Small-vessel vasculitis (ANCA…)\n   * Large vessel vasculitis (Behcet disease, Takayasu…)\n7. Suspected Inflammatory disease with cardiovascular involvement:\n\n   * Sarcoidosis\n   * Still disease\n\nExclusion Criteria:\n\n1. Inability to provide non-opposition\n2. History of heart transplant","ALL","18 Years",{"count":19,"type":20},5000,"ESTIMATED","OBSERVATIONAL","Inflammatory Cardiovascular Diseases and Autoimmune Rheumatic Diseases (ICARDs) encompass cardiovascular involvement in connective tissue diseases, vasculitis, and primary inflammatory cardiac processes affecting all layers of the heart. ICARDs are associated with increased cardiovascular morbidity and mortality, independently of traditional risk factors, via multiple pathophysiological mechanisms.\n\nDiagnosis and prognosis are challenged by the heterogeneity of clinical presentations. Multimodality cardiovascular imaging - including cardiovascular magnetic resonance (CMR), transthoracic echocardiography, and positron emission tomography (PET) - plays a central role in detecting and characterizing inflammatory involvement, and may offer prognostic insights.\n\nGiven the limited data on the diagnostic and prognostic utility of these imaging modalities in ICARDs, the EACVI-INFLAME study aims to assess the prevalence of confirmed cardiovascular involvement in patients with suspected or established ICARDs undergoing CMR and\u002For cardiac PET in a multicentric international cohort.",[24,25,26,27,28,29,30,31,32,33,34,35,36],"Myocarditis","ANCA Associated Vasculitis","Pericarditis","Systemic Sclerosis","Systemic Lupus Erythematosus","Idiopathic Inflammatory Myopathies","Rheumatoid Arthritis","Spondylarthritis","Behcet Disease","Takayasu Arteritis","Sarcoidosis","Still Disease","Tako Tsubo Cardiomyopathy",[38,39,40,41,42,43,44,45],"Cardiovascular disease","Auto-immune disease","Auto-inflammatory disease","Rheumatic disease","CMR","PET","multimodality imaging","ICARD","RECRUITING","2026-06-03",{"date":49,"type":50},"2026-06-05","ACTUAL",{"date":52,"type":50},"2025-11-19",{"date":54,"type":20},"2028-10-30",{"name":56,"class":57},"Assistance Publique - Hôpitaux de Paris","OTHER",1,{"id":60,"slug":61,"hasResults":11,"nctId":62,"briefTitle":63,"officialTitle":64,"acronym":65,"eligibilityCriteria":66,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":67,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":69,"conditions":70,"keywords":75,"overallStatus":46,"whyStopped":4,"lastUpdateSubmitDate":81,"lastUpdatePostDateStruct":82,"startDateStruct":84,"completionDateStruct":86,"leadSponsor":88,"locationsCount":58},"100639718","the-role-of-cd34-stem-cells-in-the-pathogenesis-of-takotsubo-syndrome-100639718","NCT07604467","The Role of CD34+ Stem Cells in the Pathogenesis of Takotsubo Syndrome","Effects of CD34+ Stem Cells on Left Ventricular Dysfunction Among Patients With Takotsubo Syndrome","STRESS","Inclusion Criteria:\n\n* Minimum age 18 years\n* Established TTS per InterTak registry criteria\n* Signed consent form\n\nExclusion Criteria:\n\n* Patients under the age of 18 years\n* Ischemic heart disease with at least one complete total occlusion\n* Other concurrent cardiomyopathies\n* Active infectious myocarditis\n* obstructive coronary artery disease\n* Previous hospital stay due to acute coronary syndrome (myocardial infarction) in the last 6 months before TTS acute event\n* Previous interventional coronary artery procedure in the last 6 months before TTS acute event\n* Significant valvular heart disease\n* Significant peripheral artery occlusive disease\n* Active or remitted hematologic malignancy\n* Patients receiving immunosuppressive therapy\n* Significant comorbiditeis affecting patients survival (malignancy)\n* Failure to obtain freely given, informed consent form.",{"count":68,"type":20},40,"The underlying mechanisms of microvascular dysfunction in Takotsubo cardiomyopathy remain incompletely understood. As CD34+ cells are essential to coronary microvascular homeostasis we will investigate the potential association between CD34+ cell count and changes in left ventricular function in patients with Takotsubo cardiomyopathy at baseline and 6-month follow-up.",[36,71,72,73,74],"Microvascular Dysfunction","CD34+ Stem Cells","Heart Failure","Cardiac Contractility Recovery",[76,77,78,79,80],"Takotsubo syndrome","CD34+ stem cells","heart failure","microvascular dysfunction","cardiac contractility recovery","2026-05-17",{"date":83,"type":50},"2026-05-22",{"date":85,"type":50},"2021-09-06",{"date":87,"type":20},"2026-12-31",{"name":89,"class":57},"University Medical Centre Ljubljana",{"id":91,"slug":92,"hasResults":11,"nctId":93,"briefTitle":94,"officialTitle":95,"acronym":4,"eligibilityCriteria":96,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":97,"enrollmentInfo":98,"targetDuration":100,"studyType":21,"phases":4,"briefSummary":101,"conditions":102,"keywords":4,"overallStatus":46,"whyStopped":4,"lastUpdateSubmitDate":106,"lastUpdatePostDateStruct":107,"startDateStruct":109,"completionDateStruct":111,"leadSponsor":113,"locationsCount":58},"100336663","registry-of-patients-with-takotsubo-syndrome-100336663","NCT03663348","Registry of Patients With Takotsubo Syndrome","NYU Takotsubo (Broken Heart Syndrome) Registry","Inclusion Criteria:\n\n* Physician diagnosis of takotsubo syndrome\n* Age\\>18 years\n\nExclusion Criteria:\n\n\\- Lack of capacity to provide informed consent","110 Years",{"count":99,"type":20},500,"10 Years","Takotsubo syndrome is a condition which mimics acute myocardial infarction, and is diagnosed in 1.5% to 2.2% of patients referred to hospital with suspected acute coronary syndrome. It is also known as broken heart syndrome, takotsubo cardiomyopathy, stress cardiomyopathy and apical ballooning cardiomyopathy, among other names. The pathogenesis of this disorder is not well understood. Possible mechanisms include catecholamine excess, coronary artery spasm, microvascular dysfunction, among others. This is a multicenter, nation-wide, observational study of patients who were previously diagnosed with takotsubo syndrome. The investigators aim to use this registry to help plan and carry out further studies and to improve understanding of the pathophysiologic mechanisms of this syndrome. In addition participants will be followed for events, and to monitor quality of life and stress.",[103,104,105],"Takotsubo Cardiomyopathy","Broken Heart Syndrome","Tako-tsubo Cardiomyopathy","2025-12-23",{"date":108,"type":50},"2025-12-30",{"date":110,"type":50},"2009-09-11",{"date":112,"type":20},"2029-08-01",{"name":114,"class":57},"NYU Langone Health",{"id":116,"slug":117,"hasResults":11,"nctId":118,"briefTitle":119,"officialTitle":119,"acronym":120,"eligibilityCriteria":121,"healthyVolunteers":122,"sex":16,"minAge":123,"maxAge":124,"enrollmentInfo":125,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":127,"conditions":128,"keywords":4,"overallStatus":46,"whyStopped":4,"lastUpdateSubmitDate":134,"lastUpdatePostDateStruct":135,"startDateStruct":137,"completionDateStruct":139,"leadSponsor":141,"locationsCount":58},"100547562","cardiomyopathies-and-heart-muscle-diseases-cardiac-imaging-in-the-evaluation-of-myocardial-fibrosis-transition-100547562","NCT06409585","Cardiomyopathies and Heart Muscle Diseases: Cardiac Imaging in the Evaluation of Myocardial Fibrosis Transition","CHIEFTain","Inclusion Criteria:\n\nHFpEF cohort\n\n* Male or female between 30 to 90 years old\n* Provision of informed consent prior to any study specific procedures\n* Patients with symptomatic heart failure with preserved ejection fraction as defined by the presence of heart failure symptoms (dyspnoea, reduced exercise tolerance, fatigue), signs (elevated jugular venous pressure, pulmonary crackles, peripheral oedema) as well as echocardiographic features (preserved left ventricular systolic function (\\>50%) and reduced diastolic function with septal e' \\\u003C7cm\u002Fs or lateral e' \\\u003C10cm\u002Fs).\n\nHypertrophic cardiomyopathy cohort\n\n* Male or female between 30 to 90 years old\n* Provision of informed consent prior to any study specific procedures\n* Established diagnosis of hypertrophic cardiomyopathy: left ventricular wall thickness \\>15mm by any imaging modality without a loading condition to explain the hypertrophy OR\n* Left ventricular wall thickness of \\>13 mm by any imaging modality in the presence of a genetic or non-genetic component, supported by other features including family history, non-cardiac symptoms, ECG changes and laboratory tests.\n\nHypertensive heart disease cohort\n\n* Male or female between 30 to 90 years old\n* Provision of informed consent prior to any study specific procedures\n* Diagnosis of essential hypertension for at least 1 year with evidence of left ventricular hypertrophy on echocardiography (left ventricular mass index \\>98 g\u002Fm2 and relative wall thickness \\>0.42)\n\nArrhythmogenic cardiomyopathy\n\n* Male or female between 30 to 90 years old\n* Provision of informed consent prior to any study specific procedures\n* Diagnosis of arrhythmogenic right ventricular cardiomyopathy based on the International Task Force 2010 criteria\n\nMyocarditis cohort\n\n* Male or female between 30 to 90 years old\n* Provision of informed consent prior to any study specific procedures\n* Diagnosis of myocarditis in the past month defined with the following features\n\n  * Chest pain\n  * Evidence of pericarditis (pericardial rub, ST- segment elevation or pericardial effusion)\n  * Elevated serum troponin\n  * Unobstructed coronary arteries on coronary angiogram OR\n  * Cardiac magnetic resonance imaging evidence of myocarditis (subepicardial or mid-wall late gadolinium enhancement\n\nTakotsubo cardiomyopathy cohort\n\n* Male or female between 30 to 90 years old\n* Provision of informed consent prior to any study specific procedures\n* Diagnosis of takotsubo cardiomyopathy in the past month as defined by European Society of Cardiology guidelines 2018\n\nCardiac sarcoidosis cohort\n\n* Male or female between 30 to 90 years old\n* Provision of informed consent prior to any study specific procedures\n* Diagnosis of cardiac sarcoidosis for at least 1 year based on expert consensus opinion with\n\n  * Histological diagnosis from a myocardial biopsy OR\n  * Histological diagnosis of extra-cardiac sarcoid AND\n\nOne or more of following is present\n\n* Steroid +\u002F- immunosuppressant responsive cardiomyopathy or heart block\n* Unexplained reduced LVEF (\\\u003C40%)\n* Unexplained sustained (spontaneous or induced) VT\n* Mobitz type II 2nd degree heart block or 3rd degree heart block\n* Patchy uptake on dedicated cardiac PET (in a pattern consistent with CS)\n* Late Gadolinium Enhancement on CMR (in a pattern consistent with CS)\n* Positive gallium uptake (in a pattern consistent with CS) AND\n* Other causes for the cardiac manifestation(s) have been reasonably excluded\n\nExclusion Criteria:\n\n* Inability or unwilling to give informed consent.\n* History of claustrophobia or inability to tolerate supine position for the PET\u002FMR or PET\u002FCT scans.\n* Impaired renal function with eGFR of \\\u003C30 mL\u002Fmin\u002F1.73 m2.\n* Women who are pregnant or breastfeeding.\n* Iodine or gadolinium contrast allergy\n* Contra-indication to CT scanning",true,"30 Years","90 Years",{"count":126,"type":20},290,"Heart scarring, also known as fibrosis, plays a major role in a lot of heart muscle abnormalities. These abnormalities of the heart muscle can lead to major issues such as symptoms of heart failure, dangerous heart rhythm disturbances and even death. However, a lot of these conditions are still not fully understood and treatment options are limited. We here aim to use a new radioactive dye called 68Ga-FAPI to identify patterns and the activity of heart muscle scarring. This radioactive dye is being used in humans particularly in identifying and monitoring cancers and has shown promise in identifying scarring in the heart as well. This will help us not only understand the underlying disease process and risk stratify these patients but also potentially help us develop new targeted therapies that can affect heart muscle scarring. Participants will undergo a baseline MRI scan using this new dye and a plain MRI scan will repeated 12-18 months after to see if there are any changes in the process.",[129,130,131,132,36,133,24],"Heart Failure With Preserved Ejection Fraction","Hypertrophic Cardiomyopathy","Cardiac Sarcoidosis","Hypertensive Heart Disease","Arrhythmogenic Right Ventricular Cardiomyopathy 1","2025-08-18",{"date":136,"type":50},"2025-08-19",{"date":138,"type":50},"2023-05-01",{"date":140,"type":20},"2028-01-01",{"name":142,"class":57},"University of Edinburgh",{"id":144,"slug":145,"hasResults":11,"nctId":146,"briefTitle":147,"officialTitle":147,"acronym":148,"eligibilityCriteria":149,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":124,"enrollmentInfo":150,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":152,"conditions":153,"keywords":4,"overallStatus":46,"whyStopped":4,"lastUpdateSubmitDate":154,"lastUpdatePostDateStruct":155,"startDateStruct":157,"completionDateStruct":159,"leadSponsor":161,"locationsCount":58},"100567574","characterisation-of-the-biochemical-profile-and-physiology-of-the-coronary-circulation-in-takotsubo-syndrome-100567574","NCT06669962","Characterisation of the Biochemical Profile and Physiology of the Coronary Circulation in Takotsubo Syndrome","TAKO-PROVE","Inclusion Criteria:\n\n* Age ≥ 18 years;\n* Diagnosis of Takotsubo syndrome\n* Signing of informed consent\n\nExclusion Criteria:\n\n* Age \\\u003C18 years;\n* Refusal to sign written informed consent.",{"count":151,"type":20},50,"Consecutive consenting patients over the age of 18 years diagnosed with Takotsubo syndrome according to the position statement of the European Journal of Heart Failure (2016) will be included in the study. The primary endpoint is to evaluate the incidence of coronary microcirculation dysfunction and its correlation with the clinical presentation and the prognosis in patients with TAKO-Tsubo syndrome. Secondary endpoints will be to assess the incidence of in-hospital mortality, the prevalence of cardiogenic shock, the correlation between the levels of biomarkers analyzed, microvascular dysfunction, perceived quality of life, and angina severity during hospitalization and at subsequent follow-ups, and the influence of knowledge of the level of microvascular dysfunction on clinical management and prescribed therapies. Enrolment: 2 years, follow-up: 1 month and 1 year. Total: 3 years.",[36],"2024-10-31",{"date":156,"type":50},"2024-11-01",{"date":158,"type":50},"2024-07-10",{"date":160,"type":20},"2027-06-27",{"name":162,"class":57},"A.O.U. Città della Salute e della Scienza","Tako-TSUBO Cardiomyopathy"]